The Midas List 2013: Who has the Golden Touch in Life Sciences?

Raising capital is an important step to the success of any SME biotech company. This year’s Midas List 2013 complied by Forbes ranks the best dealmakers in high-tech and life science venture capital.

This year 2 life science investors made the 2013 Midas List. These investors and many other venture capitalists play an important role in the innovation and successes of biotech SMEs, without which many life saving drugs might not be developed. Here Pharma IQ takes a closer look at their achievements.   

Bryan Roberts, Ph.D., Partner, Venrock

Rank: 75
Times on Midas: 5
This is Roberts 5th time on the Midas List after first making the list in 2008. This year Bryan Roberts, Ph.D. is ranked #75 and is widely considered to be one of the best performing healthcare investors around. Bryan joined Venrock as Kauffman Fellow in 1997 and focuses on a broad range of healthcare investments. He is currently Chairman of the Board of Directors of Achaogen, Castlight Health and Ironwood Pharmaceuticals (NASDAQ: IRWD).

Jonathan T. Silverstein, J.D., Partner, OrbiMed

Rank: 96
Times on Midas: 2

Silverstein joined OrbiMed in 1999 to focus on private equity and structured transactions in small capitalisation public biotechnology and medical device companies. Silverstein first featured on the Midas List in 2012 and is back again this year at #96. Silverstein has backed some of the biggest recent exits in the industry and was also the chairman of Enobia Pharma, which sold for $1.1 billion in February 2012 as the largest VC-backed biotech deal, and an early investor in Intercept Pharmaceuticals (NASDAQ: ICPT), which went public in October 2012 and is the top post-2012 IPO performer in biotech.

Have Your Say
Rate this feature and give us your feedback in the comments section below